Sodium/glucose cotransporter: Difference between revisions
No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| (6 intermediate revisions by one other user not shown) | |||
| Line 2: | Line 2: | ||
== Function == | == Function == | ||
'''Sodium/glucose cotransporter''' (SGLT) is responsible for glucose absorption across membranes. SGLT1 and SGLT2 which are expressed in different tissues, have similar active sites but differ in their non-active site structures. SGLT1 is responsible of glucose absorption in the small intestine and SGLT2 in kidney<ref>PMID:26125647</ref>. | '''Sodium/glucose cotransporter''' (SGLT) is responsible for glucose absorption across membranes. SGLT1 and SGLT2 which are expressed in different tissues, have similar active sites but differ in their non-active site structures. '''SGLT1''' is responsible of glucose absorption in the small intestine and '''SGLT2''' in kidney<ref>PMID:26125647</ref>. | ||
== Disease == | == Disease == | ||
| Line 14: | Line 14: | ||
== Structural highlights == | == Structural highlights == | ||
The drug | The drug Dapagliflozin contains a <scene name='10/1042600/Cv/5'>glucose moiety which stacks against residue Y290</scene> of SGLT2. The <scene name='10/1042600/Cv/6'>glucose moiety forms multiple H-bonds</scene> to SGLT2<ref>PMID:38057552</ref>. Water molecule is shown as red sphere. | ||
See also: | |||
*[[Canagliflozin]] | |||
*[[Dapagliflozin]] | |||
*[[Empagliflozin]] | |||
==3D structures of sodium/glucose cotransporter== | ==3D structures of sodium/glucose cotransporter== | ||